May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
The Compatibility of Vitrase® Combined with Kenalog®
J.A. Gow; B.A. Aird; T.R. McNamara; C.K. Song; T.W. Joe; G.A. Baklayan
Author Affiliations & Notes
  • J.A. Gow
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • B.A. Aird
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • T.R. McNamara
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • C.K. Song
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • T.W. Joe
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • G.A. Baklayan
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • Footnotes
    Commercial Relationships  J.A. Gow, ISTA Pharmaceuticals®, Inc., E; B.A. Aird, ISTA Pharmaceuticals®, Inc., E; T.R. McNamara, ISTA Pharmaceuticals®, Inc., E; C.K. Song, ISTA Pharmaceuticals®, Inc., E; T.W. Joe, ISTA Pharmaceuticals®, Inc., E; G.A. Baklayan, ISTA Pharmaceuticals®, Inc., E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 688. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The Compatibility of Vitrase® Combined with Kenalog®
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J.A. Gow, B.A. Aird, T.R. McNamara, C.K. Song, T.W. Joe, G.A. Baklayan; The Compatibility of Vitrase® Combined with Kenalog® . Invest. Ophthalmol. Vis. Sci. 2006;47(13):688.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To determine the compatibility of Vitrase® (hyaluronidase for injection) lyophilized, ovine (6200 USP units/vial) and Kenalog®–40 (triamcinolone acetonide, 40 mg/mL), when combined.

Methods: : Vitrase (6200 USP units/vial) was reconstituted with 0.54 mL of sterile, unpreserved normal saline (0.9% sodium chloride for injection) and combined with Kenalog to obtain a concentration of approximately 68 USP units per 100 µL of Kenalog. This Vitrase/ Kenalog mixture used is a 1:1 clinical dose ratio. Hyaluronidase activity in the presence and absence of Kenalog was determined using a viscometric method derived from the European Pharmacopeia procedure.

Results: : Vitrase activity remained unchanged for the sample preparation (68 USP units per 100 µL of Kenalog) after 24 hours.

Conclusions: : Hyaluronidase activity remained unchanged for a sample concentration of Vitrase prepared at 68 USP units per 100 µL of Kenalog after 24 hours. In the in vitro setting, Vitrase was found to retain full biological activity and stability when combined with Kenalog.

Keywords: corticosteroids • inflammation • retina 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept